Christopher Furman - Nov 11, 2022 Form 3/A - Amendment Insider Report for Vitro Biopharma, Inc. (NONE)

Role
Chief Executive Officer, Director
Signature
/s/ Christopher Furman
Stock symbol
NONE
Transactions as of
Nov 11, 2022
Transactions value $
$0
Form type
3/A - Amendment
Date filed
6/30/2023, 08:35 PM
Date Of Original Report
Nov 14, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NONE Employee Stock Option (Right to Buy) Nov 11, 2022 Common Stock 5M $1.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option became exercisable as to 1,000,000 shares on July 6, 2022, and will become exercisable as to (i) 1,000,000 shares on July 6, 2023, (ii) 1,000,000 shares on July 6, 2024, (iii) 1,000,000 shares on July 6, 2025, and (iv) 1,000,000 shares on July 6, 2026.

Remarks:

This amendment is filed solely to reflect the proper exercise price for the stock options granted.